These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 1712765

  • 1. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
    Gedik O, Ozdemir T, Akalin S.
    Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
    [Abstract] [Full Text] [Related]

  • 2. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ, Ladenson PW.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [Abstract] [Full Text] [Related]

  • 3. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
    Khanna CM, Shankar LR, Jaggi CB, Bansal JK, Chugh P.
    J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
    [Abstract] [Full Text] [Related]

  • 4. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE, Michanek AM, Holmberg EC, Fink M.
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [Abstract] [Full Text] [Related]

  • 5. Short and long term effects of radioiodine and antithyroid drugs on T4 binding proteins, free T4 and T3, during Graves' disease therapy.
    Jaffiol C, Baldet L, Robin M, Papachristou C, Lapinski H, Mirouze J.
    Horm Metab Res; 1977 Jan; 9(1):73-81. PubMed ID: 66177
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
    Nygaard B, Jarløv AE, Kristensen LO, Faber J.
    Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
    [Abstract] [Full Text] [Related]

  • 7. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 8. [Clinical aspects, diagnosis and drug therapy of hyperthyroidism].
    Bürgi U, Gerber H, Peter HJ.
    Schweiz Med Wochenschr; 1995 Aug 08; 125(31-32):1489-94. PubMed ID: 7545825
    [Abstract] [Full Text] [Related]

  • 9. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A.
    N Engl J Med; 1996 Jan 25; 334(4):220-4. PubMed ID: 8531998
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
    Bayer MF, Kriss JP, McDougall IR.
    J Nucl Med; 1985 Nov 25; 26(11):1248-56. PubMed ID: 3840528
    [Abstract] [Full Text] [Related]

  • 11. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J, Kuma K, Mozai T.
    J Clin Endocrinol Metab; 1986 May 25; 62(5):980-3. PubMed ID: 3754263
    [Abstract] [Full Text] [Related]

  • 12. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L, De Palma D, Ceriani L, Vanoli P, Garancini S, Tordiglione M, Tarolo GL.
    Radiol Med; 2000 Dec 25; 100(6):480-3. PubMed ID: 11307510
    [Abstract] [Full Text] [Related]

  • 13. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T, Sato A, Komiya I, Nishimori T, Ito Y, Terao A, Eto S, Tanaka Y.
    J Clin Endocrinol Metab; 2000 Aug 25; 85(8):2775-8. PubMed ID: 10946880
    [Abstract] [Full Text] [Related]

  • 14. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J, Hosoya T, Naito N, Yoshimura H, Kohno Y, Tarutani O, Kuma K, Sakane S, Takeda K, Mozai T.
    J Clin Endocrinol Metab; 1988 Jan 25; 66(1):147-52. PubMed ID: 3335601
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.
    Burman KD, Dimond RC, Earll JM, Wright FD, Wartofsky L.
    J Clin Endocrinol Metab; 1976 Sep 25; 43(3):606-13. PubMed ID: 989049
    [Abstract] [Full Text] [Related]

  • 16. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
    Andrade VA, Gross JL, Maia AL.
    J Clin Endocrinol Metab; 1999 Nov 25; 84(11):4012-6. PubMed ID: 10566642
    [Abstract] [Full Text] [Related]

  • 17. Value of simultaneous T3, T4, and TSH measurements for management of graves' disease in children.
    Golden MP, Kaplan SA, Lippe BM, Lee WN.
    Pediatrics; 1977 May 25; 59(5):762-7. PubMed ID: 577011
    [Abstract] [Full Text] [Related]

  • 18. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.
    Nuklearmedizin; 2007 May 25; 46(3):77-84. PubMed ID: 17549318
    [Abstract] [Full Text] [Related]

  • 19. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H, Kuwert T, Lohmann T.
    Exp Clin Endocrinol Diabetes; 2004 Apr 25; 112(4):171-4. PubMed ID: 15127319
    [Abstract] [Full Text] [Related]

  • 20. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
    Kawamura S, Kishino B, Tajima K, Mashita K, Tarui S.
    J Clin Endocrinol Metab; 1983 Mar 25; 56(3):507-12. PubMed ID: 6185525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.